西妥珠单抗
| 单克隆抗体 | |
|---|---|
| 种类 | ? |
| 目標 | ROR1 |
| 臨床資料 | |
| 其他名稱 | UC-961 |
| 法律規範狀態 | |
| 法律規範 |
|
| 识别信息 | |
| CAS号 | 1643432-38-5  |
| UNII | |
西妥珠单抗（英语：cirmtuzumab；开发代号：UC-961），或译次妥珠单抗，是一种抗ROR1人源化单克隆抗体。[1][2]
它是一种处于早期临床试验中的实验药物，用于治疗包括慢性淋巴细胞白血病（CLL）在内的多种癌症。[3][4]
参考资料
[编辑]- ^ Choi MY, Widhopf GF, Castro J, Li H, Kidwell RL, Zhang SC, et al. Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts. Blood. 2015, 126 (23): 1736 [2024-03-10]. doi:10.1182/blood.V126.23.1736.1736. （原始内容存档于2019-09-13）.
- ^ Researchers to test novel drug combination against toughest breast cancers. Medical Express. 2018-08-27 [2024-03-10]. （原始内容存档于2023-04-06）.
- ^ Clinical trial number NCT03420183 for "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies" at ClinicalTrials.gov
- ^ 1st Mantle Cell Lymphoma Patient Dosed in Phase 1/2 Trial Testing Cirmtuzumab-Imbruvica Combo. Lymphoma News Today. 2018-05-18 [2024-03-10]. （原始内容存档于2023-04-07）.